Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00120757
Status:
COMPLETED
Last Update Posted:
2011-12-22
First Post:
2005-07-11
Brief Title:
Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis ANRS120
Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Organization:
French National Agency for Research on AIDS and Viral Hepatitis
Study Overview
Official Title:
Efficacy of Alendronate Versus Placebo in the Treatment of HIV-1 Associated Osteoporosis a Multicenter Randomized Controlled Trial ANRS 120 Fosivir
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Osteopenia and osteoporosis are being described more frequently in people with HIV infection This study will test the efficacy of alendronate in comparison with a placebo after 2 years in people with primary osteoporosis People will receive the recommended adequate intake of calcium and vitamin D
Detailed Description:
The purposes of this trial are
To study the efficacy of alendronate in HIV-associated osteoporosis
To measure the prevalence of osteoporosis in HIV patients and to detect risk factors in a large cohort of HIV patients from the screening phase
To study the efficacy of alendronate in HIV-associated osteoporosis
To measure the prevalence of osteoporosis in HIV patients and to detect risk factors in a large cohort of HIV patients from the screening phase
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ANRS120 Fosivir | None | None | None |